welcome to cyprotex
welcome to cyprotex adme
cloe predict
cloe select
cloe screen

The Cyprotex Discovery Bus

 
Collaboration Opportunities

Let us talk to you about how the Discovery Bus can help your business. We are keen to collaborate with external partners to trial and develop the Discovery Bus further.

An integrated IT solution for the drug discovery industry

Cyprotex’s Discovery Bus is an integrated IT solution for the drug discovery industry which automates decision making and information processing. It enables the steps carried out by a human expert to be modelled as a workflow and the decomposition of a more complex task into series of linked steps, each step of which can be implemented by specialist programs known as agents. Intelligent workflow techniques identify when an agent should be called and which tasks are appropriate for an agent to solve. A collection of specialist agents work together in a highly organized and efficient manner with other agents providing management and control.

The applications of the Discovery Bus are numerous and extend to a number of different industries. However some examples of the main applications which are relevant to the Drug Discovery industry include auto-QSAR and laboratory workflow processes which streamline the flow of compounds into assays and, subsequently, the capture and interpretation of instrument data.

 
 
Specifications of the Discovery Bus +
Unique Features of the Discovery Bus +
Applications of the Discovery Bus +
References

1 Cartmell J et al. (2005) J Comput Aided Mol Des 19; 821-33.

2 Cartmell J et al. (2007) Curr Opin Drug Discov Devel 2007 10; 347-52.

discovery bus

Download a copy of the product sheet

Cloe® is a registered trade mark owned by Cyprotex PLC

careerscontactlegalprivacy
This website was last updated
on 3rd February 2012
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.